Abstract | OBJECTIVES: METHODS: RESULTS: At week 2 after the start, a clinical response (deltaCDAI > or = 70) was observed in 6/10 patients (median = 305 [294-418] to 166 [107-392]), with reduction in serum C-reactive protein levels (median = 17.2 [6.8-67.2] to 9.1 [0.9-17.2] mg/dl). Colonoscopies showed a reduction in inflammatory lesions in the four patients who attained remission (CDAI < 150), whereas the inflammatory score of the biopsies did not decrease significantly. No moderate or severe adverse events were observed. CONCLUSIONS:
|
Authors | G D'Haens, C Swijsen, M Noman, L Lemmens, J Ceuppens, H Agbahiwe, K Geboes, P Rutgeerts |
Journal | The American journal of gastroenterology
(Am J Gastroenterol)
Vol. 96
Issue 9
Pg. 2564-8
(Sep 2001)
ISSN: 0002-9270 [Print] United States |
PMID | 11569676
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Immunoglobulin G
- Immunosuppressive Agents
- Receptors, Tumor Necrosis Factor
- Etanercept
|
Topics |
- Adolescent
- Adult
- Aged
- Crohn Disease
(drug therapy, pathology)
- Etanercept
- Female
- Humans
- Immunoglobulin G
(therapeutic use)
- Immunosuppressive Agents
(therapeutic use)
- Male
- Middle Aged
- Pilot Projects
- Receptors, Tumor Necrosis Factor
(therapeutic use)
|